Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally

Market Focus

May 21

On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.

The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.

The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162345639"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162345639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162345639?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162345639","market":"us","top_or_hot":-1,"title":"Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally","media":"Market Focus","content":"<p><p>On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.</p><p>The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.</p><p>The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-21 10:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.</p><p>The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.</p><p>The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1162345639","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162345639","pubTimestamp":1779329149,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"走势警报|PegBio常规交易下跌5.14%，在多日上涨后，禁售期到期担忧持续回调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}